ArticleGlobal advances in integrative medicine and health
Impact of the ACEMg Biomedicine on Sensorineural Hearing Loss and Auditory Function: Analysis of Real-World Clinical Data.
Article in Global advances in integrative medicine and health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hearing loss is a chronic disability that affects the lives and livelihoods for over 1.5 billion people worldwide. Hearing aids are the predominant treatment; however, their impact is modest, and they are less available in low- and middle-income countries where the need is greatest. Moreover, hearing loss is the #1 mid-life risk factor for dementia. Sensorineural hearing loss (SNHL), the most common form of hearing loss, is a metabolic stress disorder. Objective: The micronutrient formula ACEMg was developed to block SNHL and successfully tested on animal models. We report real-world data (RWD) from a real-world evidence (RWE) study (N = 190) conducted to assess whether ACEMg impacts SNHL in humans. Methods: This was a retrospective observational cohort study design with a historical comparison group. RWD from distortion product otoacoustic emissions (OAE) examinations were collected from patients previously diagnosed with SNHL. OAE testing is a recognized marker of cochlear health, producing objective measures of the auditory function of outer hair cells (OHC) in the cochlea. Results: Analyses of RWD from OAE examinations in the treatment group (N = 93), who used ACEMg as softgel capsules, compared with OAE RWD from the untreated group (N = 97) suggest that ACEMg is significantly associated with the preservation and improvement of auditory function. Overall, OAE scores remained unchanged or improved for 75.3% of those in the ACEMg treatment group, as contrasted with 26.8% in the no ACEMg group. OAE scores over 2 years remained unchanged for 37.6% and improved for 37.7%. OAE scores decreased for 73.2% of those in the untreated group Conclusion: This study yielded statistically reliable, objective, real-world clinical data suggesting a potential association between ACEMg supplementation and higher OAE scores over time, although alternative explanations cannot be excluded. These findings warrant additional investigation, given the widespread incidence of SNHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.